Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have